Abcam ups rabbit mAb presence with acquisition of Calico Biolabs

monoclonal antibodies
U.K. life sciences company Abcam expanded its presence in rabbit monoclonal antibodies with the acquisition of California’s Calico Biolabs. (Novasep)

U.K. life sciences company Abcam has expanded its presence in rabbit monoclonal antibodies with the acquisition of California’s Calico Biolabs for an undisclosed price.

Calico develops custom high-quality recombinant rabbit monoclonal antibodies for diagnostic and biopharmaceutical companies. With the deal, Abcam gets Calico’s catalog of ready-made CAL antibodies for immunohistochemistry as well as its custom development services.

“This acquisition significantly expands our leadership in recombinant rabbit monoclonal antibody technology,” Joyce Young, an Abcam vice president, said in a statement. “The combination of our complementary antibody engineering capabilities will further support our mission to provide our customers with access to the best antibodies for both today’s and tomorrow’s targets of interest.”

CONFERENCE

AI Innovations for Life Science and Healthcare Summit East

Join the expert speaking faculty of over 30 life science, healthcare, and tech professionals on June 13–14, 2019, in Philadelphia, as we elevate clinical trial operations, healthcare outcomes, and supply chain implementation through AI. Use Discount Code 796819FIERCE to save 15% off the standard registration rate.

Last year, Abcam made a run at gene editing specialist Horizon Discovery for a deal that would have been worth $367 million. However, Horizon rejected the offer and instead of sweetening the deal Abcam hit the pause button on the move.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.